Edit

HBM Healthcare Investments

https://hbmhealthcare.com
Last activity: 07.07.2025
Active
News
335
Portfolio
4
Mentions
71
Employees: 11-50
Investment Stage: Series B; IPO

Portfolio 4

DateNameWebsiteTotal RaisedLocation
28.03.2023ArriVent B...arrivent.com$415MUnited Sta...
17.10.2022Odyssey Th...odysseytx.com$487MUnited Sta...
18.06.2019Viela Bio ...vielabio.com$600MUnited Sta...
28.04.2017Amicusamicuspharma.eu$21.79MSwitzerlan...

News 335

DateTitleDescription
30.06.2025HBM Healthcare Investments AG completes share buyback programmeOn 27 June 2025, HBM Healthcare Investments AG concluded its 2022 share buyback programme, which was initiated in June 2022. A total of 252,610 shares of HBM Healthcare Investments AG were repurchased via a separate trading line on the SIX ...
15.05.2025Ad hoc announcement pursuant to Art. 53 LR2024/2025 financial year: HBM Healthcare achieved profit of CHF 19 million in a challenging environment HBM Healthcare Investments generated an annual profit of CHF 19 million in the 2024/2025 financial year in a challenging environment. The net asset value per share (NAV) rose by 1.5 percent, while the share price declined slightly by –2.6 ...
01.04.2025Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments expects to report a net profit of CHF 19 million for the 2024/2025 financial yearIn a market environment that remains difficult for the biotech sector, HBM Healthcare Investments closed the 2024/2025 financial year with a net profit of CHF 19 million as of 31 March. Net asset value per share (NAV) rose by 1.5 percent to...
20.03.2025Ad hoc announcement pursuant to Art. 53 LRSanofi to acquire DR-0201, a clinical-stage program of HBM portfolio company Dren Bio, for upfront amount of USD 600 million, plus potential milestonesHBM Healthcare Investments (SIX: HBMN) today announced that Dren Bio, a private portfolio company, and Sanofi have entered into a definitive agreement under which Sanofi has agreed to acquire DR-0201, a targeted bispecific myeloid cell enga...
20.01.2025Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes Quarterly Report as at 31 December 2024 with key figures for the first nine months of the 2024/2025 financial year Positive result for the first nine months ended 31 December 2024 HBM Healthcare Investments generated a profit of CHF 66 million in the first nine months of the 2024/2025 financial year ended 31 December 2024. The performance in the first ...
03.01.2025Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments reports a compelling 15 percent increase in NAV in the 2024 calendar yearHBM Healthcare Investments closed the calendar year 2024 with a strong performance. Its net asset value (NAV) per share rose by 15 percent to CHF 251.17. By contrast, the share price failed to reflect this good performance, growing only mar...
18.12.2024Ad hoc announcement pursuant to Art. 53 LRSuccessful IPO of HBM portfolio company Sai Life Sciences on the Indian stock exchanges NSE and BSE increases NAV per HBM share by 3.2 percentSai Life Sciences (NSE/BSE: SAILIFE), a portfolio company of HBM Healthcare Investments, made a successful debut on the Indian stock exchanges NSE and BSE today. The company raised new capital of INR 9.5 billion (CHF 100 million) by issuing...
21.10.2024Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments publishes Half-Year Report as at 30 September 2024 with key figures for the first six months of the 2024/2025 financial year Successful first half – currency effects impact performance HBM Healthcare Investments generated a profit of CHF 23 million for the first six months of the 2024/2025 financial year ended 30 September 2024. Net asset value per share (NAV) r...
14.10.2024HBM portfolio company Upstream Bio raises USD 255 million in successful initial public offeringUpstream Bio (Nasdaq: UPB), a previously private company in the HBM Healthcare Investments portfolio, got off to a successful start on the stock market last Friday. The company raised USD 255 million in new capital through the issuance of 1...
01.10.2024Ad hoc announcement pursuant to Art. 53 LRHBM Healthcare Investments posts half-year profit of CHF 23 million for 2024/2025 financial year; currency effects had a strong negative impact on the resultHBM Healthcare Investments achieved a positive performance in the first half of the 2024/2025 financial year. The net asset value per share (NAV) increased by 1.5 per cent to CHF 244.34. The share price rose by 1.7 per cent to CHF 189.40. B...
Show more

Mentions in press and media 71

DateTitleDescription
25.06.2025Neuron23: Pioneering Precision Medicine with a $96.5 Million BoostIn the ever-evolving landscape of biotechnology, Neuron23 stands as a beacon of hope. This San Francisco-based company has just secured $96.5 million in Series D funding, a significant leap forward in its mission to develop precision medici...
25.06.2025Neuron23 Raises $96.5M in Series D FinancingNeuron23, a San Francisco, CA-based clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases, raised $96.5M in Series D funding. The round wa sled by heal...
24.06.2025Neuron23: $96.5 Million Series D Raised For Advancing Neurological And Immunological MedicinesNeuron23 – a clinical-stage biotechnology company focused on developing precision medicines for genetically defined neurological and immunological diseases – announced the closing of a $96.5 million Series D funding round led by a healthcar...
28.05.2025FORE Biotherapeutics: A New Dawn in Cancer Treatment with $38 Million Series D-2 FinancingIn the ever-evolving landscape of cancer treatment, a new player is making waves. FORE Biotherapeutics, based in Philadelphia, has secured $38 million in Series D-2 financing. This funding marks a significant step forward in the company's m...
23.05.2025FORE Biotherapeutics: $38 Million Series D-2 Raised For Advancement Of PlixorafenibFORE Biotherapeutics, a registration-stage biotherapeutics company focused on developing targeted therapies to treat cancer patients, announced a $38 million Series D-2 financing. For this initial close of the Series D-2, leading healthcare...
18.03.2025Curevo's $110 Million Bet on Shingles Vaccine: A Game Changer in ImmunizationIn the bustling world of biotechnology, Curevo Vaccine has made headlines with its recent $110 million Series B funding round. This infusion of capital is not just a financial boost; it’s a lifeline for a company on the brink of a significa...
18.03.2025Curevo: $110 Million (Series B) Raised For Advancing Amezosvatein ShinglesCurevo Vaccine – a privately-held clinical-stage biotechnology company dedicated to developing varicella zoster virus (VZV) vaccines with improved tolerability – announced the closing of a $110 million Series B round to advance the developm...
17.03.2025Curevo Raises $110M in Series B FundingCurevo, a Seattle, WA-based clinical-stage biotechnology company, raised $110M in Series B funding. The round was led by Medicxi, with participation from OrbiMed, HBM Healthcare Investments, and Sanofi Ventures plus existing investors RA Ca...
10.01.2025Numab Therapeutics: A Financial Surge in the Fight Against CancerIn the world of biotechnology, where innovation meets investment, Numab Therapeutics has made headlines with its recent financial maneuvering. The Swiss company, known for its pioneering work in multi-specific antibodies, has successfully c...
09.01.2025Numab raises additional CHF50 million In 2024 Numab caused a stir with the acquisition of the biotech’s spin-out Yellow Jersey Therapeutics by Johnson & Johnson for $1.25 billion. Numab’s immuno-oncology therapeutic NM26 entered the clinic and the company started a collabo...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In